BNGO on Nasdaq
BioNano Genomics
Company in San Diego, United States.1
Price unavailable
Last updated Oct 16, 2026.
Overview
2003Founded1
Compare with EyePoint Pharmaceuticals, Precipio, Inc. or RAPID MICRO BIOSYSTEMS, INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Consumable Revenue brought in 49% of the revenue BioNano Genomics broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Consumable Revenue | $12.8M | $14.0M |
| Software Revenue | $6.2M | $6.4M |
| Instrument Revenue | $8.0M | $6.4M |
| Product and Service, Other | $3.8M | $1.8M |
Regions
EMEA brought in 49% of the revenue BioNano Genomics broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| EMEA | $14.2M | $14.1M |
| Americas | $13.6M | $12.2M |
| Asia Pacific | $2.9M | $2.2M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue25¢$15.3M
- Research and development18¢$11.4M
- Selling, general and admin57¢$35.1M
- Income tax0¢$67.0K
Out of $28.5M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $28.5M | $30.8M |
| Total cost of revenue | $15.3M | $30.4M |
| Research and development | $11.4M | $24.8M |
| Selling, general and administrative | $35.1M | $51.9M |
| Intangible assets and other long-lived assets impairment | $0 | $19.7M |
| Restructuring costs | $0 | $8.0M |
| Total operating expenses | $46.5M | $104.4M |
| Loss from operations | -$33.3M | -$104.0M |
| Interest income | $1.1M | $2.1M |
| Other income (expense) | $5.9M | -$10.1M |
| Total other income (expense) | $7.0M | -$8.0M |
| Loss before income taxes | -$26.3M | -$112.0M |
| Provision for income taxes | -$67.0K | -$33.0K |
| Net loss | -$26.4M | -$112.0M |
| Net loss per share, basic (in dollars per share) | -$4.85 | -$88.13 |
| Weighted-average common shares outstanding, basic (in shares) | 5.4M shares | 1.3M shares |
| Net loss per share, diluted (in dollars per share) | -$4.85 | -$88.13 |
| Weighted-average common shares outstanding, diluted (in shares) | 5.4M shares | 1.3M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $3.0M | $9.2M | |
| Investments | $16.3M | $302.0K | |
| Accounts receivable, net | $5.2M | $4.8M | |
| Inventory | $5.4M | $11.1M | |
| Prepaid expenses and other current assets | $5.2M | $3.1M | |
| Restricted investments | $10.3M | $11.0M | |
| Total current assets | $45.4M | $39.5M | |
| Restricted cash | $0 | $400.0K | |
| Property and equipment, net | $14.8M | $19.2M | |
| Operating lease right-of-use assets | $3.2M | $1.8M | |
| Finance lease right-of-use assets | $3.1M | $3.3M | |
| Intangible assets, net | $4.3M | $9.7M | |
| Other long-term assets | $2.7M | $2.8M | |
| Total assets | $73.6M | $76.7M | |
| Accounts payable | $5.6M | $7.0M | |
| Accrued expenses | $5.5M | $5.6M | |
| Contract liabilities | $967.0K | $1.1M | |
| Operating lease liability | $697.0K | $3.0M | |
| Finance lease liability | $249.0K | $260.0K | |
| Convertible debentures payable (at fair value) | $10.0M | $20.4M | |
| Total current liabilities | $22.9M | $37.3M | |
| Operating lease liability, net of current portion | $2.5M | $145.0K | |
| Finance lease liability, net of current portion | $3.5M | $3.5M | |
| Long-term contract liabilities | $249.0K | $267.0K | |
| Total liabilities | $29.2M | $41.3M | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.0001 par value; 400,000,000 shares authorized at December 31, 2025 and 2024; 10,740,200 and 1,865,400 shares issued and outstanding at December 31, 2025 and 2024, respectively | $1.0K | $0 | |
| Additional paid-in capital | $764.0M | $728.6M | |
| Accumulated deficit | -$719.6M | -$693.2M | |
| Accumulated other comprehensive income | $17.0K | $27.0K | |
| Total stockholders equity | $44.4M | $35.4M | |
| Total liabilities and stockholders equity | $73.6M | $76.7M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | |
| Common stock, shares issued (in shares) | 10.7M shares | 1.9M shares | |
| Common stock, shares outstanding (in shares) | 10.7M shares | 1.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (Loss) | -$26.4M | -$112.0M |
| Depreciation and amortization expense | $9.5M | $14.0M |
| Inventory write-offs | $0 | $7.2M |
| Amortization of financing lease right-of-use asset | $204.0K | $204.0K |
| Accretion of interest on securities | -$976.0K | -$1.3M |
| Net realized loss on investments | $0 | $14.0K |
| Non-cash lease expense | $893.0K | $122.0K |
| Gain on lease modification | -$450.0K | -$73.0K |
| Stock-based compensation | $4.5M | $9.7M |
| Cost of leased equipment sold to customer | $704.0K | $361.0K |
| Change in fair value of contingent consideration | $0 | -$10.9M |
| Change in fair value of convertible debentures, convertible notes payable and option liability | -$5.2M | -$8.1M |
| Loss on issuance of convertible debentures | $0 | $1.9M |
| Gain on High Trail extinguishment | $0 | -$4.0M |
| Loss on extinguishment of convertible debentures payable | $0 | $7.3M |
| Disposal of internal-use software | $0 | $1.3M |
| Intangible assets and other long-lived assets impairment | $0 | $17.9M |
| Long-lived assets held for sale impairment | $0 | $425.0K |
| Right-of-use-asset impairment | $0 | $1.4M |
| Disposal of property and equipment | $258.0K | $1.4M |
| Accounts receivable | -$448.0K | $4.1M |
| Inventory | $4.9M | -$587.0K |
| Prepaid expenses and other current assets | -$2.1M | $1.6M |
| Other long-term assets | $60.0K | $4.7M |
| Accounts payable | -$1.4M | -$3.4M |
| Accrued expenses, contract liabilities, and lease liabilities, net | -$580.0K | -$2.2M |
| Net cash used in operating activities | -$16.3M | -$68.9M |
| Purchases of property and equipment | $0 | -$103.0K |
| Purchase of available for sale securities | -$241.9M | -$233.0M |
| Sale and maturities of available for sale securities | $229.1M | $307.0M |
| Net cash provided by (used in) investing activities | -$12.7M | $73.8M |
| Principal payments of financing lease liability | -$71.0K | -$58.0K |
| Proceeds from sale of common stock and warrants | $31.1M | $44.4M |
| Offering expenses on sale of common stock and warrants | -$2.1M | -$3.0M |
| Proceeds from sale of common stock under employee stock purchase plan | $0 | $11.0K |
| Proceeds from warrant and option exercises | $9.0K | $4.0K |
| Proceeds from issuance of convertible debentures | $0 | $18.0M |
| Payments on High Trail notes | $0 | -$61.0M |
| Payments on convertible debentures | -$4.9M | -$5.0M |
| Debt issuance costs on sale of convertible debentures | $0 | -$1.7M |
| Payments of retirement fees for redemption of High Trail notes | $0 | -$5.4M |
| Net cash provided by (used in) financing activities | $24.0M | -$13.7M |
| Effect of exchange rates on cash and cash equivalents and restricted cash | -$11.0K | -$7.0K |
| Net decrease in cash and cash equivalents and restricted cash | -$5.1M | -$8.8M |
| Cash paid for interest | $1.7M | $10.7M |
| Cash paid for operating lease liabilities | $2.4M | $2.8M |
| Transfer of instruments and servers from inventory into property and equipment, net | $757.0K | $5.3M |
| Issuance of common stock for convertible debentures payable | $350.0K | $0 |
| Accrued liability for fees to be paid in common stock | $0 | $1.6M |
| Fees paid in common stock | $1.6M | $0 |
| Operating lease liabilities resulting from obtaining right-of-use assets | $3.0M | $0 |
| Non-cash Fill-Up Amount | $0 | $491.0K |
Former names
Timeline
Recent filings
- Sep 14, 20268-K
- Sep 9, 20264
- Aug 21, 20264
- Aug 14, 2026SCHEDULE 13G/A
- Aug 10, 20268-K
- Aug 10, 202610-Q
- Aug 5, 20263
- Aug 5, 20263
- Aug 5, 20263
- Aug 5, 20263
- Aug 5, 20264
- Aug 5, 20264
- Aug 5, 20264
- Aug 5, 20264
- Jul 30, 20263
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitebionanogenomics.com1
- X (Twitter)x.com/bionanogenomics1
- Instagramwww.instagram.com/bionanogenomics1
- WikidataQ30265338
- SEC EDGARCIK 1411690
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataBioNano Genomics on Wikidata
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11